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Abstract
Haem oxygenase (heme,hydrogen-donor:oxygen oxidoreductase (α-methene-oxidizing, hydroxylating)), E.C.
1.14.99.3, converts heme into biliverdin and carbon monoxide, utilizing NADPH as cofactor.
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This is a citation summary for Haem oxygenase in the Guide to Pharmacology database (GtoPdb). It exists
purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation
analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here
under database links.
GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a
reference work which is most usefully represented as an on-line database. As in any publication this work
should be appropriately cited, and the papers it cites should also be recognized. This document provides a
citation for the relevant parts of the database, and also provides a reference list for the research cited by those
parts.
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